Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- Chugai Sues 4 Companies Including Iwaki Seiyaku for Patent Infringement Related to Oxarol Ointment
February 21, 2013
- HIV Treatment Dolutegravir Gets FDA Priority Review: ViiV Healthcare
February 21, 2013
- Radium-223 Granted Priority Review Status by US FDA: Bayer HealthCare
February 19, 2013
- DSP Targets Sales of 450 Billion Yen in FY2017 by Making Latuda Blockbuster
February 19, 2013
- Blopress Retakes Top Spot in Domestic Ethical Drug Market in 2012: IMS Japan
February 19, 2013
- Kowa Says Listing Application for Livalo Generic “Won’t Be Filed”; Possibility Nixed for 1st AG in Japan
February 18, 2013
- No Statistical Significance Shown in OS between Tivozanib and Sorafenib in PIII Study: Astellas
February 18, 2013
- Nihon Medi-Physics to Establish New Manufacturing Base for PET Diagnostics in Fujioka City, Gunma Prefecture
February 18, 2013
- Small and Medium Sized Pharmacies Jointly Buys Generics Directly from Manufacturers
February 15, 2013
- Takeda Subsidiary Suspends Operations for 12 Days Due to Alinamin-F5 Injection Recalls
February 15, 2013
- Daiichi Sankyo to Launch New Firm for Duchenne Muscular Dystrophy Therapy Jointly with Govt-Backed Fund
February 15, 2013
- Nichi-Iko to Open Representative Office in Thailand on April 1
February 14, 2013
- AZ Takes Over GLP-1 Receptor Agonist Bydureon from Eli Lilly in Japan
February 14, 2013
- Allegra, Allelock Face Stiff Competition from Generics in Anti-Allergic Drug Market
February 14, 2013
- Otsuka Holdings Pharmaceutical Sales Up 3.4% in April-December Thanks to Abilify Sales Hike
February 14, 2013
- Samsca 7.5 mg Tablets Approved: Otsuka
February 14, 2013
- Novartis Will Explain to Doctors that 2009 Article on Diovan Is Invalid: President Mitani
February 13, 2013
- Bristol-Myers, Pfizer Underline Eliquis’s Superiority vs. Warfarin
February 13, 2013
- Novartis Sales Up 2.5% in 2012 Thanks to Rapid Growth in New Fields
February 13, 2013
- Sales of 10 Top European, US Drug Makers See Sharp Declines in 2012 Due to Patent Cliff
February 13, 2013
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…